New compounds reduce debilitating inflammation

Two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis have been discovered by researchers. The compounds, dubbed OD36 and OD38, appear to curtail inflammation-triggering signals from RIPK2. RIPK2 is an enzyme that activates high-energy molecules to prompt the immune system to respond with inflammation.

SIX Case Western Reserve scientists are part of an international team that has discovered two compounds that show promise in decreasing inflammation associated with diseases such as ulcerative colitis, arthritis and multiple sclerosis. The compounds, dubbed OD36 and OD38, specifically appear to curtail inflammation-triggering signals from RIPK2 (serine/threonine/tyrosine kinase 2). RIPK2 is an enzyme that activates high-energy molecules to prompt the immune system to respond with inflammation. The findings of this research appear in the Journal of Biological Chemistry.

Continue reading